Éric Dansin

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Benjamin Besse, Mélinda Charrier, Valérie Lapierre et al. · OncoImmunology · 2015 · 782 citations · Full text

Life Sciences, Immunology, Oncology +16

Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

Julien Mazières, Solange Peters, Benoît Lepage et al. · Journal of Clinical Oncology · 2013 · 659 citations

Medicine, Molecular Genetics, Oncology +15

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

Élisabeth Quoix, Gérard Zalcman, Jean-Philippe Oster et al. · The Lancet · 2011 · 575 citations

Medicine, Geriatric Medicine, Oncology +10

Randomized Phase III Trial of Sequential Chemoradiotherapy Compared With Concurrent Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique–Groupe Français de Pneumo-Cancérologie NPC 95-01 Study

P. Fournel, G. Robinet, P. Thomas et al. · Journal of Clinical Oncology · 2005 · 546 citations

Medicine, Oncology, Radiation Oncology +13